Volume 60, Issue 6, Pages (December 2011)

Slides:

Advertisements

Similar presentations

Volume 60, Issue 5, Pages (November 2011)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 2, Pages (August 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 44, Issue 6, Pages (December 2003)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 59, Issue 3, Pages (March 2011)

Volume 60, Issue 2, Pages (August 2011)

Volume 65, Issue 4, Pages (April 2014)

Volume 56, Issue 3, Pages (September 2009)

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 3, Pages (September 2007)

Volume 51, Issue 3, Pages (March 2007)

Volume 72, Issue 4, Pages (October 2017)

Let the Games Begin (with EAU Approval)

Volume 68, Issue 1, Pages (July 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg

Volume 66, Issue 3, Pages (September 2014)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 52, Issue 1, Pages (July 2007)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 59, Issue 3, Pages (March 2011)

Volume 54, Issue 4, Pages (October 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 66, Issue 5, Pages (November 2014)

Volume 55, Issue 3, Pages (March 2009)

Volume 69, Issue 4, Pages (April 2016)

Volume 73, Issue 6, Pages (June 2018)

Volume 64, Issue 3, Pages (September 2013)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

The PSA Era is not Over for Prostate Cancer

Volume 65, Issue 2, Pages (February 2014)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 73, Issue 5, Pages (May 2018)

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 50, Issue 5, Pages (November 2006)

Volume 50, Issue 3, Pages (September 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 74, Issue 5, Pages (November 2018)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 72, Issue 2, Pages (August 2017)

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology is “Your” Journal

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Axel Heidenreich European Urology Supplements

Volume 143, Issue 6, (December 2010)

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 67, Issue 4, Pages (April 2015)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

Volume 60, Issue 6, Pages 1251-1257 (December 2011) Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01) Stéphane Culine, Aude Fléchon, Aline Guillot, Sylvestre Le Moulec, Damien Pouessel, Frédéric Rolland, Alain Ravaud, Nadine Houédé, Laurent Mignot, Florence Joly, Stéphane Oudard, Sophie Gourgou European Urology Volume 60, Issue 6, Pages 1251-1257 (December 2011) DOI: 10.1016/j.eururo.2011.08.072 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram. GEM=gemcitabine; GEMOX=gemcitabine plus oxaliplatin. European Urology 2011 60, 1251-1257DOI: (10.1016/j.eururo.2011.08.072) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Overall survival according to treatments. GEM=gemcitabine; GEMOX=gemcitabine plus oxaliplatin. European Urology 2011 60, 1251-1257DOI: (10.1016/j.eururo.2011.08.072) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Overall survival according to stratification factors. GFR=glomerular filtration rate; PS=performance status. European Urology 2011 60, 1251-1257DOI: (10.1016/j.eururo.2011.08.072) Copyright © 2011 European Association of Urology Terms and Conditions